Growth of Mycoplasma pneumoniae was completely prevented by 0.06 gg of actinomycin D/ml, and 0.00375 ,g/ml caused 90% inhibition. It thus appears that M. pneumoniae is more susceptible to actinomycin D than previously reported. Low concentrations (0.019 ug/ml) of the antibiotic primarily inhibited ribonucleic acid synthesis and high concentrations (20 yg/ml) inhibited both ribonucleic and deoxyribonucleic acid synthesis.
Mycoplasma pneumoniae appears to be more susceptible to actinomycin D than was previously reported by Tourtellotte (3). Because of Tourtellotte's report and the observation that actinomycin D (0.5 ,g/ml) inhibits glucose uptake of Escherichia coli spheroplasts (1), the present investigation was conducted.
M. pneumoniae obtained from the American Type Culture Collection (ATCC 15293), was grown in Difco PPLO broth supplemented with 20% gamma globulin-free horse serum, 10% fresh yeast extract, and 0.5% glucose; the viable titer was measured in acid-forming units (AFU) with the aid of phenol red indicator.
Actinomycin D (Merck Sharp and Dohme, West Point, Pa., and Calbiochem, La Jolla, Calif.) was dissolved in distilled water (100 ,ug/ml, stock solution), and the exact concentration of the stock solution was confirmed by optical density at 441 nm (e = 25.7 x 10').
Direct exposure of antibiotic solutions to light was avoided at all times.
The effect of actinomycin D on M. pneumoniae viability was determined by preparing dilutions of mycoplasma in growth medium containing the selected concentrations of the chromopeptide. All samples were incubated at 37 C and examined daily for acid production. Periodically, actively multiplying mycoplasma were checked for typical colonial morphology on a suitable agar-containing mycoplasma medium. AFU titers (log) were recorded on the 21st day of incubation.
To facilitate the washing procedures utilized in the 3H-uridine or 3H-thymidine uptake experiments, M. pneumoniae was grown as monolayers in screw-cap tubes (16 by 125 mm) at 37 C. M. pneumoniae monolayers (10' to 109 376 AFU/tube) were exposed to various concentrations of actinomycin D. After 1 h of exposure to the antibiotic, 9H-uridine was added (final concentration, 2.5 ,uCi/ml) and incubation was continued. Samples were monitored for trichloroacetic acid-insoluble incorporation. Similar studies were conducted with 3H-thymidine, but a concentration of 4 ,uCi/ml was utilized. All samples were processed as follows. Triplicate tubes of each group were drained and washed with three 2-ml volumes of trichloroacetic acid. The trichloroacetic acid-insoluble fractions were drained and solubilized in 0.5 ml of hydroxide of Hyamine and 10 ml of scintillation counting fluid [2,5-diphenyloxazole, 4 g; 1,4-bis -(2-(4 -methyl-5-phenyl-oxazolyl)) -benzene, 200 mg; toluene, 950 ml; and absolute ethanol, 50 ml]. Activity per sample was monitored in a Packard Tri-Carb scintillation counter, model 3320.
M. pneumoniae viability was completely inhibited by actinomycin D at a concentration of 0.06 sg/ml. Growth of this infectious agent was suppressed by >90% and nearly 100% at antibiotic levels of 0.0075 to 0.015 ,ug/ml and 0.03 ,ug/ml, respectively (Table 1) .
Ribonucleic acid (RNA) synthesis ( H-uridine uptake) was inhibited 73.2% by 0.019 ,ug of actinomycin D/ml (Table 2) . A 1,000-fold increase in the antibiotic resulted in only an additional 22.6% inhibition.
M. pneumoniae 3H-thymidine uptake in the presence of the chromopeptide was inhibited by 48.4 and 97% at 1.25 and 20 sg/ml, respectively (Table 2) .
It thus appears that M. pneumoniae is more susceptible to actinomycin D than previously reported. In comparison, inhibition of mam- depending on the source of the antibiotic and the medium in which the antibiotic is being utilized.
